REPORTING OF CARDIOVASCULAR RISK FACTORS IN LANDMARK IMMUNE CHECKPOINT INHIBITOR TRIALS

被引：0
|
作者：
Tan, Sean
Sivakumar, Seiyon
Segelov, Eva
Nicholls, Stephen J.
Nelson, Adam J.
机构：
[1] Victorian Heart Inst, Melbourne, Vic, Australia
[2] Monash Heart, Melbourne, Vic, Australia
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2023年 / 81卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1154-007
引用
收藏
页码：2168 / 2168
页数：1
相关论文
共 50 条
  • [21] Adverse Event Reporting Quality in Cancer Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy: A Systematic Review
    Wang, Yuhong
    Chen, Chen
    Du, Wei
    Zhou, Yixin
    He, Lina
    Hong, Shaodong
    Zhang, Li
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [22] Risk Reduction Reporting in Cardiovascular Clinical Trials
    Iyengar, Rupa L.
    Esquitin, Ricardo
    Shah, Kshitij A.
    Razzouk, Louai
    Bashey, Sameer
    Aneja, Ashish
    Mathew, Verghese
    Farkouh, Michael E.
    CIRCULATION, 2010, 122 (21)
  • [23] Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape
    Zhu, Han
    Ivanovic, Maja
    Nguyen, Andrew
    Nguyen, Patricia K.
    Abc, Sean M. Wu
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2021, 160 : 121 - 127
  • [24] Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer
    Li, Xuemeng
    Yang, Fang
    Liu, Baogang
    Ye, Leiguang
    Du, Jingwen
    Fan, Xiaona
    Yu, Yue
    Li, Mengwei
    Bu, Li
    Zhang, Zhuoqi
    Xie, Lili
    Li, Wuquan
    Qi, Jiaqing
    JOURNAL OF IMMUNOTHERAPY, 2024, 47 (06) : 220 - 226
  • [25] Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
    Mohr, Raphael
    Jost-Brinkmann, Fabian
    Ozdirik, Burcin
    Lambrecht, Joeri
    Hammerich, Linda
    Loosen, Sven H.
    Luedde, Tom
    Demir, Munevver
    Tacke, Frank
    Roderburg, Christoph
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [26] Survivorship Bias in Analyses of Immune Checkpoint Inhibitor Trials Reply
    Toi, Yukihiro
    Sugawara, Shunichi
    JAMA ONCOLOGY, 2019, 5 (08) : 1226 - 1227
  • [27] Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease
    Lutgens, Esther
    Seijkens, Tom T. P.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [28] Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor
    le Seve, Julien Denis
    Guedon, Alexis F.
    Bordenave, Stephanie
    Agard, Christian
    Connault, Jerome
    Pistorius, Marc-Antoine
    Quereux, Gaelle
    Espitia, Olivier
    THROMBOSIS AND HAEMOSTASIS, 2023, 123 (11) : 1049 - 1056
  • [29] Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis
    Stahlbaum, Danielle
    Jablonski, Renea
    Strek, Mary E.
    Bestvina, Christine M.
    Polley, Mei-Yin
    Reid, Pankti
    RESPIRATORY MEDICINE, 2023, 217
  • [30] Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy
    Moik, Florian
    Chan, Wei-Shin Evelyn
    Wiedemann, Sarah
    Hoeller, Christoph
    Tuchmann, Felix
    Aretin, Marie-Bernadette
    Fuereder, Thorsten
    Zoechbauer-Mueller, Sabine
    Preusser, Matthias
    Pabinger, Ingrid
    Ay, Cihan
    BLOOD, 2021, 137 (12) : 1669 - 1678
12345